利肺健脾方辅助治疗对晚期NSCLC 患者 炎症因子、肿瘤标志物的影响

Effect of Lifeijianpi prescription on inflammatory factors and tumor markers in advanced NSCLC patients

摘要:

目的 探讨利肺健脾方辅助治疗对晚期非小细胞肺癌（NSCLC）患者炎症因子、肿瘤标志物的影响。 方法 将90 例晚期NSCLC 患者分为研究组和对照组，每组45 例。对照组采用多西他赛+ 顺铂（DP）或吉西他 滨+ 顺铂（GP）化疗方案治疗。研究组在对照组基础上，给予利肺健脾方治疗。根据实体瘤疗效标准评估两组疗效。 检测两组治疗前后糖类抗原125（CA125）、癌胚抗原（CEA）、糖类抗原199（CA199）、细胞角质素片段抗原 21-1（CYFRA21-1）、超敏C 反应蛋白（hs-CRP）、白细胞介素4（IL-4）、干扰素γ（IFN-γ）及白细胞介 素17（IL-17）水平。结果 两组缓解率和控制率比较，差异无统计学意义（P >0.05）；两组治疗后hs-CRP、 IL-4 及IL-17 降低，IFN-γ 升高（P <0.05）；研究组治疗后hs-CRP、IL-4 及IL-17 低于对照组，IFN-γ 高 于对照组（P <0.05）；两组治疗后CA125、CEA、CA199 及CYFRA21-1 降低（P <0.05），研究组治疗后 CA125、CEA、CA199 及CYFRA21-1 低于对照组（P <0.05）。结论 肺健脾方能有效降低晚期NSCLC 患者 肿瘤标志物的水平，减轻炎症反应。

Abstract:

Objective To investigate the effect of Lifeijianpi prescription (LP) on inflammatory factors and tumor markers in patients with advanced non-small cell lung cancer (NSCLC). Methods Totally 90 patients with advanced NSCLC were enrolled and randomly divided into study group (n = 45) and control group (n = 45). All patients were treated with Docetaxel plus Cisplatin (DP) or Gemcitabine plus Cisplatin (GP) chemotherapy. Patients in study group received additional treatment of LP. Therapeutic efficacy was evaluated according to the RECIST solid tumor efficacy criteria. Levels of hs-CRP, IL-4, IFN-γ, IL-17, CA125, CEA, CA199 and CYFRA21-1 were measured before and after treatment. Results The remission rate and control rate in two groups were similar (P > 0.05). Patients in study group experienced dramatic decrease of hs-CRP, IL-4 and IL-17, and increase of IFN-γ when compared with those in control group (P < 0.05). The two groups were treated with biochemical test including CA125, CEA, CA199 and CYFRA21-1 after treatment. Study group suggested a more significantly decreased levels of CA125, CEA, CA199 and CYFRA21-1 compared with those in control group (P < 0.05). Conclusions LP can effectively reduce levels of tumor markers and inflammatory response in advanced NSCLC patients.